BioVie Inc. has reported encouraging Phase 2b results for bezisterim in early Parkinson’s disease, with patients receiving the oral treatment showing advantages over placebo across motor symptoms, non-motor symptoms and inflammatory biomarkers. The 57-participant SUNRISE-PD trial also identified a possible inflammation-linked subgroup that could influence the design of a future Phase 3 study. The findings remain preliminary because treatment lasted only 12 weeks, several clinical measures were exploratory and most reported statistical comparisons were not adjusted for the large number of analyses performed.
SUNRISE-PD enrolled adults with early-stage Parkinson’s disease who had not previously received symptomatic treatment with carbidopa and levodopa. Participants were randomized equally to receive 20 milligrams of bezisterim or placebo twice daily, allowing researchers to assess the investigational drug without the potential masking effects of established dopaminergic treatment. The primary pharmacodynamic assessment examined a predefined panel of blood-based inflammatory indices, while clinical, quality-of-life and safety measures were used to explore the treatment’s broader profile.
The EPNIC-15 result suggests broad activity but relies on an exploratory composite measure
One of the clearest reported differences appeared on EPNIC-15, a composite developed from 15 components covering motor symptoms, non-motor problems, daily activities and sleep. The mean score changed by negative 0.04 with bezisterim and positive 0.18 with placebo, producing a large standardized effect size and a nominal p-value of 0.0006. Lower scores represented improvement, while the placebo group moved in the direction of worsening.
The composite draws selected items from the Movement Disorder Society Unified Parkinson’s Disease Rating Scale Parts I, II and III and the Parkinson’s Disease Sleep Scale. Its components include daytime sleepiness, constipation, walking and balance, tremor during daily activities, posture, toe tapping and morning tiredness. That breadth is relevant because Parkinson’s disease affects substantially more than movement, with sleep disruption, fatigue, mood changes and autonomic problems often contributing heavily to disability.
The result should not be interpreted as definitive evidence that bezisterim improves the complete spectrum of Parkinson’s disease. EPNIC-15 is not an established registrational primary endpoint, and the trial was designed mainly to identify biological and clinical signals that could guide later development. BioVie Inc. will need to show that the apparent benefits can be reproduced using accepted clinical endpoints over a longer treatment period in a larger patient population.
The company also reported statistically significant advantages across individual Parts I, II and III of the Movement Disorder Society scale, particularly among participants with higher baseline platelet concentrations. However, BioVie Inc. did not provide complete numerical results for every clinical scale in the topline announcement, limiting independent assessment of the absolute size and clinical importance of those changes.
Higher platelet levels may offer a Phase 3 enrichment strategy rather than a confirmed biomarker
Participants with baseline platelet counts above 230,000 per microliter, representing approximately half of the study population, showed more pronounced treatment differences across EPNIC-15 and the major Movement Disorder Society scale components. BioVie Inc. suggested that platelet concentration could help enrich a future trial with patients more likely to demonstrate a robust response, rather than being used to exclude everyone below the threshold.
The proposed relationship fits the company’s central hypothesis that neuroinflammation and metabolic dysfunction contribute to Parkinson’s disease progression. Platelets carry biological characteristics linked to neuronal pathology, although a routine platelet count is not currently an established predictive biomarker for choosing Parkinson’s treatment.
Subgroup findings can appear stronger than results in the overall trial, especially when researchers examine numerous biomarkers and outcome measures in a small population. The platelet threshold therefore requires prospective confirmation. A future study would ideally define the enrichment strategy before enrollment and demonstrate that the selected population consistently benefits from bezisterim.
The biomarker findings supplied additional evidence that the drug affected its intended pathways. A composite measure of neuroinflammation changed by negative 0.28 with bezisterim compared with positive 0.19 for placebo, with a nominal p-value of 0.0018. BioVie Inc. also reported favorable changes in inflammatory proteins and said 283 of 380 measured proteins shifted in a direction associated with a lower inflammatory burden.
Exploratory neuronal-injury biomarkers, including neurofilament light chain, glial fibrillary acidic protein and microtubule-associated protein tau, also moved favorably. The composite neuronal-injury signal declined with bezisterim and increased with placebo, while neurofilament light chain produced a nominal p-value of 0.008. These measurements support biological target engagement but do not prove that bezisterim slows the underlying neurodegenerative process. The United States Food and Drug Administration has not validated the reported biomarkers as surrogate endpoints for Parkinson’s disease approval.
Short treatment duration and unadjusted analyses remain the central limitations
The trial’s randomized, double-blind and placebo-controlled design provides stronger evidence than an uncontrolled study. Its hybrid decentralized structure also allowed some assessments to occur in participants’ homes, potentially reducing geographic and mobility barriers that can make Parkinson’s research difficult. Motor examinations were recorded and reviewed through centralized expert scoring procedures.
The small sample and 12-week treatment period limit what the study can establish. Parkinson’s disease progresses over years, and symptom measurements can fluctuate with sleep, stress, activity and normal day-to-day variation. A disease-modifying claim would require substantially longer follow-up showing that treated patients decline more slowly than those receiving placebo or standard care.
Statistical interpretation also requires caution. BioVie Inc. disclosed that, unless otherwise stated, the reported p-values were nominal and unadjusted for multiplicity. Testing many biomarkers, subgroups and clinical outcomes increases the probability that some comparisons will appear statistically significant by chance. The consistency across several domains is encouraging, but a properly powered Phase 3 trial will need a clearly defined primary endpoint and a statistical plan that controls the risk of false-positive conclusions.
Safety was favorable during the short study. Adverse events occurred in 39.3% of bezisterim-treated participants and 51.7% of those receiving placebo. No severe or serious adverse events were reported, and each group had one treatment-related adverse event. Longer studies involving more participants will be necessary to identify less common risks and determine whether twice-daily treatment remains tolerable over extended use.
A sharp stock decline shows investors remain concerned about evidence and financing
BioVie Inc. shares traded near $1 during the August 6 session, down approximately 51% from the previous close after moving between about $0.84 and $2.41. Trading volume exceeded 7.5 million shares, while the company’s market capitalization stood near $61 million.
The severe decline despite positive headline findings suggests investors focused on the exploratory nature of the analyses, the lack of multiplicity adjustment, the absence of a disclosed Phase 3 plan and BioVie Inc.’s financial position. That interpretation is an inference from the market reaction rather than a confirmed explanation from individual shareholders.
BioVie Inc. reported approximately $13.1 million in cash and equivalents at March 31, 2026, after using $14.9 million in operating activities during the preceding nine months. The company recorded a quarterly net loss of approximately $5.3 million and disclosed substantial doubt about its ability to continue as a going concern without additional financing.
The financing issue is particularly important because a larger Parkinson’s disease trial would require substantially more capital than the completed Phase 2b study. BioVie Inc. may need an equity raise, development partnership or another strategic transaction before launching a potentially registrational program, creating possible dilution for existing shareholders.
The SUNRISE-PD results provide a reasonable basis for continued development and suggest that inflammation-focused treatment deserves further investigation in early Parkinson’s disease. The next trial must simplify the statistical question, prospectively test any platelet-based enrichment strategy and demonstrate durable clinical benefit using accepted endpoints. Until those steps are completed, bezisterim remains a promising but high-risk program supported by exploratory evidence rather than a confirmed disease-modifying therapy.
